Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2022 Earnings Call Transcript

Jonathan Foster: Sure. Jeff, yes, you should see the levels we had, and the third quarter and fourth quarter continue both in R&D and G&A in the first two quarters, and then it should drop off. You have the initial payments to CROs as you start up the trials and manufacturing, the drug Annamycin takes a lot of time. So, the lead time is quite long. So, those expenses will come earlier in the trials. So, you should see a tail off beginning in the mid half of this year, hence the $43 million can get us into the third quarter of 2024.

Jeff Jones: Perfect. Thanks guys.

Operator: Thank you. We reached the end of our question-and-answer session. I would like to turn the floor back over to Wally for any further or closing comments.

Walter Klemp: Well, again, really appreciate everybody’s time and attention. And I hope you can tell the level of excitement on the Moleculin side of things is really ramped up. And we think it’s for good reason. And like we said in sort of the Q&A portion here, things could move fairly quickly here. And that’s why we really want to encourage people to start really paying attention and really drilling down on what we are doing and why we are doing it, because like I said things are going to happen quickly. Thanks again so much for your time and have a great rest of the week.

Operator: Thank you. That does conclude today’s teleconference and webcast, and we disconnect your line at this time and have a wonderful day. We thank you for your participation today.